Premium
Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma
Author(s) -
Arora Anubha,
Bhatt Vijaya Raj,
Liewer Susanne,
Armitage James O.,
Bociek R. Gregory
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12570
Subject(s) - brentuximab vedotin , medicine , desensitization (medicine) , refractory (planetary science) , discontinuation , lymphoma , methylprednisolone , oncology , gastroenterology , hodgkin lymphoma , receptor , astrobiology , physics
Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29‐yr‐old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic reaction during the second dose of brentuximab vedotin. A 12‐step desensitization protocol was followed; after premedicating with antihistaminic agents, methylprednisolone and montelukast, a total dose of 156 mg of brentuximab vedotin (1.8 mg/kg) was given as three infusions with increasing rate and concentration. Such desensitization protocol can allow safe administration of brentuximab vedotin and may have a broader applicability in managing hypersensitivity reactions with other monoclonal antibodies.